Shiyun Xing

Shiyun Xing

Auto-generated profile, based on publicly available information

Shiyun Xing

Department of Thoracic Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
SXShiyun Xing
Shiyun Xing
ZFZhenhai Fan
Zhenhai Fan
LSLei Shi
Lei Shi
ZYZe Yang
Ze Yang
YBYuju Bai
Yuju Bai
Radiation necrosis (RN) is one of the complications of radiotherapy. Angiogenesis is a key factor underlying the development of RN, and Endostar, a safe and well-tolerated recombinant human endostatin, has been used to treat a variety of tumors. Thus far, however, no definitive reports on the use of Endostar for RN treatment have been reported. Here, we report the successful treatment of one patient with symptomatic brain radiation necrosis (BRN) using Endostar in combination with short-term hyperbaric oxygen therapy (HBO). One triple-negative breast cancer patient with recurrent brain metastatic lesions after standard chemoradiotherapy was referred to a specialty center outside our hospital for stereotaxic radiotherapy. Two months later, the patient showed deteriorating clinical symptoms, and magnetic resonance imaging (MRI) showed radiation necrosis with significant surrounding edema. The patient had a poor response to mannitol and steroids. After diagnosing this patient with BRN, we began short-term HBO therapy and intravenously administered Endostar for 4 cycles. The patient responded well to this strategy, showing rapidly and dramatically improved MRI findings and clinical symptoms. No tumor progression was observed at 10 months after treatment. Endostar in combination with short-term HBO therapy had marked effects on symptomatic BRN. However, additional large-scale, double-blinded, controlled trials are necessary to confirm the clinical effect of Endostar in combination with a short-term HBO therapy regimen on BRN.

19 March 2026 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
GYGuojun Yue
Guojun Yue
LYLingyun Yue
Lingyun Yue
YCYan Chen
Yan Chen
HYHeng Yang
Heng Yang
XCXi Chen
Xi Chen
YBYiju Bai
Yiju Bai
Introduction: A trypsin inhibitor, the serine peptidase inhibitor, Kazal type 1 (SPINK1), a secreted protein, has been identified in recent years as contributing to the advancement of specific cancer types. Lung cancer is a common class of malignant tumors. However, the role of SPINK1 in lung cancer is unknown. This study aimed to investigate the profound mechanism of SPINK1 in lung cancer. Methods: In this study, we used bioinformatics methods to select lung cancer samples for single-cell sequencing analysis, including CNV analysis, GSVA analysis, mimetic timing analysis, and intercellular communication, to identify potential molecular targets and pathways. We selected A549 cells and SPC-A1 cells to evaluate the role of SPINK1 in tumorigenesis in vitro. Results: The study indicated that SPINK1 expression was significantly elevated in tumor tissue compared with normal tissue, and higher levels correlated with poorer patient prognosis. Moreover, when SPINK1 was overexpressed, both BEAS-2B and SPC-A1 cells formed dense cell clusters, and SPINK1 overexpression significantly promoted the formation of cell clones. Discussion: Amlodipine (AML) treatment decreases mRNA and protein expression of CDK1, BCL-2, CyclinE1, and CCND1 in A549 and SPC-A1 cells by targeting SPINK1, which regulates glycolytic metabolism Conclusion: The present study suggests that SPINK1 may modulate glycolytic metabolism in lung cancer cells, inhibiting their growth and proliferation, and potentially providing therapeutic insights.